New Outcomes Data Presented at IDWeek 2014

11月 6th, 2014 / Nanosphere, A Luminex Company

A study depicting the clinical and economic impact associated with implementing the Verigene® Gram-Positive Blood Culture Test (BC-GP) in combination with antimicrobial stewardship was recently presented by Maggie Box, Pharm.D, of Scripps Health at the 2014 IDWeek meeting. This multi-center, pre-post quasi-experimental analysis was conducted to determine the impact that implementing BC-GP with antimicrobial stewardship had on time to optimal therapy, difference in antimicrobial therapy for blood culture contaminants, hospital length-of-stay, and pharmacy and overall hospital costs.

Significant findings include:

  • 25.35 hour average reduction in time to optimal therapy (60.62 hrs pre- vs 35.27 hrs post-implementation; p < 0.01)
  • 19.7 hour average reduction in duration of therapy for contaminants (44.19 hrs pre- vs 24.49 hrs post-implementation; p = 0.02)
  • Length of Stay (LOS) Reduction
  • Hospital-wide: 5.08 day average LOS reduction (14.06 days pre- vs 8.98 days post-implementation; p = 0.02)
  • ICU: 2.81 day average LOS reduction (7.13 days pre- vs 4.32 days post-implementation; p = 0.16)
  • 5.5% reduction in hospital-acquired C. difficile
  • $10,547 average cost savings per patient ($27,245 pre- vs $16,698 post-implementation; p = 0.02)
    • $685,555 total saving across 65 patients in Verigene arm of study

    Learn more about the Verigene® Gram-Positive Blood Culture Test (BC-GP)

    Click here to download full poster from IDWeek 2014.